Development of prototype to demonstrate the production options for the use of SofMat 3D technology in sequential marking within the pharmaceutical sector.

假冒产品每年给英国经济造成的损失估计为90亿英镑(国际刑事法院商业犯罪服务参考CIB-9-0556 11-11-2009)。经济的所有领域都受到假冒商品的影响，从品牌服装到药品、汽车和航空航天零部件等关键商品。没有哪个行业能幸免于假冒产品的影响。这个问题在制药行业被认为是如此严重，以至于组织了一次年度会议(药品反假冒，2013年5月)，致力于确保药品供应链的安全，以阻止假药和假药进入。针对防伪药品的立法全球化也投入了大量时间，但根据世界卫生组织的信息，到目前为止还没有制定出简单的产品识别使用点方法。Sofmat项目将用于实施制药部门开发顺序3D标记系统的建议，该系统将与现有的批处理程序一起使用。该过程可以用于顺序标记药物，而不会在产品中掺入杂质，从而确保FDA的法律可以很容易地遵守。这一过程在市场上是独一无二的&执行简单，使用将在该项目期间开发的带有智能手机技术的阅读器。这一产品首次将假冒商品的识别置于供应链中，而不是掌握在生产商或政府机构手中。作为该制药项目的后续行动，该公司将确定该技术是否可以应用于其他行业，例如：汽车和航空航天。这些下一个市场是根据一份市场报告选择的，该报告将这些市场确定为下一个主要目标行业。

The cost to the UK economy of counterfeit products has been estimated at £9billion per year(ICC Commercial Crime Services Ref CIB-9-0556 11-11-2009). All areas of the economy areaffected by counterfeit goods, from branded clothing through critical goods such aspharmaceuticals and automotive & aerospace parts. No industry sector is immune from theeffects of counterfeit products. The problem is seen as so great in the pharmaceutical sectorthat an annual conference (Anti Counterfeiting for Pharmaceuticals, May 2013) has beenorganised, devoted to securing the pharmaceutical supply chain to stop entry of counterfeitdrugs & devices. Much time has also been devoted to globalise the legislation dealing withanti-counterfeit pharmaceutical products but no simple point of use method of productauthentification has been developed so far according to information from the World HealthOrganisation (www.who.int/impact).The SofMat project will be used to implement pharmaceutical sector suggestions to develop asequential 3D marking system that will be used side by side with the existing batch process.The process can be used to sequentially mark drugs without adulterating the product ensuringthat FDA legislations can be easily complied with. The process is unique in the marketplace& simple in execution, using a reader with smartphone technology which will be developedduring this project. This product for the first time places the identification of counterfeitgoods within the supply chain rather than in the hands of the producers or governmentalagencies. This allows a wider scope for identification & removal of counterfeit goods byallowing easy identification throughout the supply chain.As a follow up to this Pharmaceutical project the Company will determine whether thetechnology can be utilised in other sectors, eg: automotive & aerospace. These next marketshave been selected using a market report that identified these as the next prime target sectors.